DOCSLIB.ORG

Arsenic Trioxide Circumvents Multidrug Resistance Based on Different Mechanisms in Human Leukemia Cell Lines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Arsenic Trioxide Circumvents Multidrug Resistance Based on Different Mechanisms in Human Leukemia Cell Lines ANTICANCER RESEARCH 25: 991-998 (2005) Arsenic Trioxide Circumvents Multidrug Resistance Based on Different Mechanisms in Human Leukemia Cell Lines TAMAMI SEO1, YOSHIMASA URASAKI2, HARUYUKI TAKEMURA1 and TAKANORI UEDA1 1First Department of Internal Medicine and 2Division of Transfusion Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan Abstract. To determine the antitumor effect of arsenic trioxide cells (7-9). As2O3 affects numerous intracellular signal (As2O3) on multidrug-resistant cells, we applied 3 human transduction pathways and causes many alternations in leukemia cell lines: daunorubicin (DNR)-resistant cell line cellular function. These actions of As2O3 may cause the K562/D1-9, which overexpresses p-glycoprotein (Pgp); DNR induction of apoptosis, the inhibition of growth and and 1-‚-D-arabinofuranosylcytosine (Ara-C) double-resistant angiogenesis and the promotion of differentiation. cell line HL60/AD, which overexpresses multidrug resistance- The clinical efficiency of anticancer drugs is frequently associated protein (MRP1); and Bcl-2-transfected pre-B lineage limited by the emergence of a variety of mechanisms of leukemia cell line 697/Bcl-2. Interestingly, K562/D1-9 showed resistance in tumor cells. One of these mechanisms is collateral sensitivity. Only HL60/AD showed small cross related to the increased expression of efflux pumps, resistance, but 697/Bcl-2 had no resistance to As2O3. An including P-glycoprotein (Pgp) and multidrug resistance- intracellular content of glutathione (GSH) played a critical role associated protein (MRP1). Both of them are members of in sensitivity to As2O3. Buthionine-sulfoximine (BSO), which the ABC superfamily of transporters and Zhou et al. reduces the GSH content, not only increased the As2O3 reported both of these gene expressions could play an sensitivity but also conquered the MRP1- related cross important role in the outcome of chemotherapy of acute resistance in HL60/AD. In conclusion, As2O3 was effective in leukemia (10). We examined the effect of As2O3 on all 3 cell lines, suggesting that As2O3 may be a promising agent multidrug-resistant cell lines which exhibit over-expression for the treatment of multidrug-resistant leukemia. of Pgp or MRP1 genes. We also examined the sensitivity to As2O3 in the apoptosis-resistant leukemia cell line which Arsenic trioxide (As2O3), a trivalent arsenical salt, has been carries the transfected Bcl-2 gene. used for many decades in traditional Chinese medicine for the treatment of various human diseases including tumors. Materials and Methods During the last decade, the efficacy of As O in both newly 2 3 Cell culture, cell treatment and materials. Human leukemia cell lines diagnosed and relapsed patients with acute promyelocytic K562 and its daunorubicin (DNR)-resistant cell line overexpressing leukemia (APL) has been reported (1-3). Even at low Pgp, K562/D1-9 (11), human myelogenous leukemia cell line HL60 concentrations, As2O3 induced a high rate of clinical and its DNR and 1-‚-D-arabinofuranosylcytocine (Ara-C) double- remission, causing few adverse effects and only minimal resistant cell line which overexpresses MRP1, HL60/AD (12), and human pre-B lineage leukemia cell line 697/Neo and its Bcl-2- bone marrow suppression. In patients with APL, As2O3 has been shown to cause degradation of the aberrant PML- transfected cells (697/Bcl-2), which is dexamethasone resistance,(13) were cultured and passaged in RPMI 1640 (Sigma retinoic acid receptor · fusion protein, resulting in complete Chemical Co, St. Louis, MO, USA) supplemented with 10% fetal remission (4-6). Recently, experimental studies have bovine serum(FBS, Sigma-Aldrich. Co.Ltd., St. Louis, MO, USA) provided further evidence of the antiproliferative properties in a 5% CO2 incubator at 37ÆC. of As2O3 towards malignant lymphoid cells and solid tumor Reagents. As2O3 was obtained from Sigma; DNR from Meiji Seika Co.(Tokyo, Japan); etoposide (VP-16), from Nippon Kayaku Co.(Tokyo, Japan); vincristine (VCR), from Shionogi Seiyaku Co. Correspondence to: Yoshimasa Urasaki, Division of Transfusion Ltd.(Osaka, Japan); mitoxantrone (MIT), from Takeda Co. Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 (Osaka, Japan); Ara-C from Nippon Shinyaku Co.(Kyoto, Japan); Shimoaizuki, Matuoka-cho, Yoshida-gun, Fukui 910-1193, Japan. MK571 from ALEXIS (San Diego, CA, USA); buthionine sulfoximine (BSO, a selective inhibitor of Á-glutamyl cysteine Key Words: Arsenic trioxide, glutathione, multidrug-resistance, synthetase) from Nacalai Tesque (Kyoto, Japan). Other chemicals buthionine-sulfoximine, reactive oxygen species. were obtained from commercial sources. As2O3 was dissolved in a 0250-7005/2005 $2.00+.40 991 ANTICANCER RESEARCH 25: 991-998 (2005) Table I. Growth inhibition effect of As2O3 and other antileukemic agents in 3 leukemic cell lines. Cell line Drugs K562 K562/D1-9 HL60 HL60/AD 697/Neo 697/Bcl-2 As2O3 2.37±0.14 0.84±0.12* 1.40±0.34 4.54±0.10** 1.53±0.18 2.57±0.75 DNR 0.084±0.013 8.63±1.63** 0.030±0.014 0.32±0.13* ND*** ND VP-16 0.85±0.13 97.5±17.1** 0.11±0.047 6.33±1.53** ND ND VCR 0.047±0.13 1.73±0.41** ND ND ND ND MIT 0.053±0.02 3.13±1.96* 0.010±0.003 0.28±0.10* ND ND Ara-C 0.021±0.007 0.025±0.011 0.047±0.021 0.42±0.07* ND ND 4 IC50 values (mM) were determined using the MTT assay. Cells (1x10 ) were seeded and exposed to As2O3 and other antileukemic agents for 72 h. Values are means±SD of at least three independent experiments performed in triplicate. Significantly different from the parental cells (*p<0.05, **p<0.01 by Student’s t-test,*** Not determined). DNR, daunorubicin; VP-16, etoposide; VCR, vincristine; MIT, mitoxantrone small amount of 1.0N NaOH and then diluted to 1 mM with Morphological assessment. As2O3-treated or -untreated cells were phosphate-buffered saline (PBS) as the stock solution. centrifuged onto slides using Cytospin and observed using May- Giemsa staining under a light microscope. Cytotoxicity. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to determine drug sensitivity. In brief, Annexin V analysis. Annexin-V assay was performed according to 1x104 cells were seeded as a suspension (100 Ìl/well) in 96-well the instructions provided in the Annexin-V-FLOUS Staining Kit microtiter plates. The cells were incubated at 37ÆC in the continuous (Roche, Penzberg, Germany). Briefly, cells (1x106) were collected presence of drug for 72 h. Cell viability was assayed by adding 50 Ìg by centrifugation at 200 xg for 5 min and washed with ice-cold PBS of MTT dye (in PBS). After a 4-h incubation, during which activated at 200 xg for 5 min at 4ÆC. The obtained cells were suspended with cells reduced the yellow MTT salt to purple formazan, the stain was 100 Ìl incubation buffer containing 2 Ìl annexin-V and incubated eluted into the medium by the addition of 100 Ìl 2-propanol for 15 min at room temperature. Fluorescent intensities were (containing 0.04N HCl). Optical densities were measured at 595 nm. determined on a FACScan. Determinations for all experiments were made in triplicate. Results were expressed as means and SD. ROS analysis. After a 120-min incubation with or without BSO, cells were incubated with dihydrorhodamine 123 Measurement of total intracellular GSH level. Total intracellular hydrochloride(DHR)and As2O3 for 60 min at 37ÆC. ROSs in the GSH content was assayed using the total Glutathione cells were determined on a FACScan as fluorescent intensities. Quantification Kit according to the manufacturer's instructions (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Results Briefly, cells (1x106) were washed with cold PBS, suspended in 10 mmol/l HCl, and two freeze-thaw cycles were performed. Five As O induced growth inhibition. Table I shows the IC for percent 5-sulfosalicylic acid was added and centrifuged at 8000 xg 2 3 50 for 10 min at 4ÆC. The supernatant was assayed for GSH content As2O3 and other anticancer agents in the parental and according to the manufacturer's instructions. The intracellular resistant cell lines. K562/D1-9, which over-expresses Pgp, GSH content was expressed in nmol/1x106 cells. showed about 100-fold resistance to DNR and cross resistance to VCR, VP-16 and MIT. Interestingly, K562/D1-9 Flow cytometric analysis of cell-cycle status. Cells (1x106) were showed about 3-fold collateral sensitivity to As2O3 which collected by centrifugation at 200 xg for 5 min, and washed twice was significantly different from the parental cell K562. with ice-cold PBS at 200 xg for 5 min at 4ÆC. The obtained cells HL60/AD, which showed MRP1 over-expression and were suspended in 1 ml PBS and 2.5 ml of 99% ethanol was added while mixing. The cells were incubated at 4ÆC for more than 30 min, 10-fold resistance to both DNR and Ara-C, was significantly washed with PBS, suspended in 200 Ìl PBS, and 100 Ìl of RNase (5 about 3-fold more resistant to As2O3 compared with the mg/ml) was added. Incubation was continued at 37ÆC for 20 min, parental cell HL60. 697/Bcl-2 did not show resistance to followed by centrifugation at 200 xg for 5 min at 4ÆC, and washing As2O3 compared with 697/Neo. with ice-cold PBS at 200 xg for 5 min at 4ÆC. The cellular DNA was then stained by applying 500 Ìl of propidium iodide (50 Ìg/ml). The Role of GSH on collateral sensitivity to As O in K562/D1-9. stained cells were analyzed on a FACScan (Becton Dickinson, 2 3 Franklin Lakes, NJ, USA). Cells with DNA content less than the We examined the relationship between the As2O3-induced cells in the G1-phase (sub-G1) were considered as apoptotic cells growth inhibition and the intracellular level of GSH.
Load more

Recommended publications
  • CCNU-Dependent Potentiation of TRAIL/Apo2l-Induced Apoptosis in Human Glioma Cells Is P53-Independent but May Involve Enhanced Cytochrome C Release
    Oncogene (2001) 20, 4128 ± 4137 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release Till A RoÈ hn1, Bettina Wagenknecht1, Wilfried Roth1, Ulrike Naumann1, Erich Gulbins2, Peter H Krammer3, Henning Walczak4 and Michael Weller*,1 1Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of TuÈbingen, Medical School, TuÈbingen, Germany; 2Institute of Physiology, University of TuÈbingen, Medical School, TuÈbingen, Germany; 3Department of Immunogenetics, German Cancer Research Center, Heidelberg, Germany; 4Department of Apoptosis Regulation, German Cancer Research Center, Heidelberg, Germany Death ligands such as CD95 ligand (CD95L) or tumor apy may be an eective therapeutic strategy for these necrosis factor-related apoptosis-inducing ligand/Apo2 lethal neoplasms. Oncogene (2001) 20, 4128 ± 4137. ligand (TRAIL/Apo2L) induce apoptosis in radio- chemotherapy-resistant human malignant glioma cell Keywords: brain; apoptosis; neuroimmunology; cyto- lines. The death-signaling TRAIL receptors 2 kines; immunotherapy (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the non- death-inducing (decoy) receptors TRAIL-R3/DcR1 and Introduction TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the Death receptor targeting is an attractive approach of absence of a protein synthesis inhibitor, cycloheximide experimental treatment for solid tumors that are (CHX). Three of the 12 cell lines were still TRAIL/ resistant to radiotherapy and chemotherapy, including Apo2L-resistant in the presence of CHX.
    [Show full text]
  • ACNU-Based Chemotherapy for Recurrent Glioma in the Temozolomide Era
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2009 ACNU-based chemotherapy for recurrent glioma in the temozolomide era Happold, C Abstract: No standard of care for patients with recurrent glioblastoma has been defined since temo- zolomide has become the treatment of choice for patients with newly diagnosed glioblastoma. This has renewed interest in the use of nitrosourea-based regimens for patients with progressive or recurrent dis- ease. The most commonly used regimens are carmustine (BCNU) monotherapy or lomustine (CCNU) combined with procarbazine and vincristine (PCV). Here we report our institutional experience with nimustine (ACNU) alone (n = 14) or in combination with other agents (n = 18) in 32 patients with glioblastoma treated previously with temozolomide. There were no complete and two partial responses. The progression-free survival (PFS) rate at 6 months was 20% and the survival rate at 12 months 26%. Grade III or IV hematological toxicity was observed in 50% of all patients and led to interruption of treatment in 13% of patients. Non-hematological toxicity was moderate to severe and led to interruption of treatment in 9% of patients. Thus, in this cohort of patients pretreated with temozolomide, ACNU failed to induce a substantial stabilization of disease in recurrent glioblastoma, but caused a notable hematotoxicity. This study does not commend ACNU as a therapy of first choice for patients with recurrent glioblastomas pretreated with temozolomide. DOI: https://doi.org/10.1007/s11060-008-9728-9 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-10588 Journal Article Originally published at: Happold, C (2009).
    [Show full text]
  • Camptothecin Derivatives Camptothecin-Derivate Dérivés De La Camptothécine
    (19) TZZ ¥_ _T (11) EP 2 443 125 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 491/14 (2006.01) C07D 491/22 (2006.01) 26.11.2014 Bulletin 2014/48 A61P 35/00 (2006.01) A61K 31/4741 (2006.01) (21) Application number: 10790151.4 (86) International application number: PCT/US2010/038890 (22) Date of filing: 16.06.2010 (87) International publication number: WO 2010/148138 (23.12.2010 Gazette 2010/51) (54) CAMPTOTHECIN DERIVATIVES CAMPTOTHECIN-DERIVATE DÉRIVÉS DE LA CAMPTOTHÉCINE (84) Designated Contracting States: • CAO: "Preparationof 14- nitrocamptothecin...", J. AL AT BE BG CH CY CZ DE DK EE ES FI FR GB CHEM.SOC., PERKIN TRANS. 1, vol. 21, 1996, GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO pages 2629-2632, XP002684965, PL PT RO SE SI SK SM TR • CHENG KEJUN ET AL: "14-azacamptothecin: a potent water-soluble topoisomerase I poison.", (30) Priority: 17.06.2009 US 218043 P JOURNAL OF THE AMERICAN CHEMICAL 16.04.2010 US 325223 P SOCIETY 26 JAN 2005 LNKD- PUBMED: 15656613, vol. 127, no. 3, 26 January 2005 (43) Date of publication of application: (2005-01-26), pages838-839, XP002684966, ISSN: 25.04.2012 Bulletin 2012/17 0002-7863 • VADWAI VIRAL ET AL: "Insilico analysis of (73) Proprietor: Threshold Pharmaceuticals, Inc. homocamptothecin (hCPT) analogues for anti- Redwood City, California 94063 (US) tumour activity", INTERNATIONAL JOURNAL OF BIOINFORMATICS RESEARCH AND (72) Inventors: APPLICATIONS, INDERSCIENCE PUBLISHERS, • CAI, Xiaohong BUCKS, GB, vol.
    [Show full text]
  • Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake
    International Journal of Molecular Sciences Article Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake Anna Aviñó 1,2,*, Anna Clua 1,2 , Maria José Bleda 1 , Ramon Eritja 1,2,* and Carme Fàbrega 1,2 1 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain; [email protected] (A.C.); [email protected] (M.J.B.); [email protected] (C.F.) 2 Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain * Correspondence: [email protected] (A.A.); [email protected] (R.E.); Tel.: +34-934-006-100 (A.A.) Abstract: Conjugation of small molecules such as lipids or receptor ligands to anti-cancer drugs has been used to improve their pharmacological properties. In this work, we studied the biological effects of several small-molecule enhancers into a short oligonucleotide made of five floxuridine units. Specifically, we studied adding cholesterol, palmitic acid, polyethyleneglycol (PEG 1000), folic acid and triantennary N-acetylgalactosamine (GalNAc) as potential enhancers of cellular uptake. As expected, all these molecules increased the internalization efficiency with different degrees depending on the cell line. The conjugates showed antiproliferative activity due to their metabolic activation by nuclease degradation generating floxuridine monophosphate. The cytotoxicity and apoptosis assays showed an increase in the anti-cancer activity of the conjugates related to the floxuridine oligomer, but this effect did not correlate with the internalization results. Palmitic and folic acid conjugates provide the highest antiproliferative activity without having the highest internalization Citation: Aviñó, A.; Clua, A.; Bleda, results.
    [Show full text]
  • Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer
    pharmaceutics Review Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer Sibusiso Alven, Xhamla Nqoro , Buhle Buyana and Blessing A. Aderibigbe * Department of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa; [email protected] (S.A.); [email protected] (X.N.); [email protected] (B.B.) * Correspondence: [email protected] Received: 24 November 2019; Accepted: 30 December 2019; Published: 29 April 2020 Abstract: Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer. Keywords: breast cancer; lung cancer; chemotherapy; polymer-based carriers; polymer-drug conjugates 1. Introduction Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]. It is the second cause of death worldwide, followed by cardiovascular diseases [2]. It is characterized by an abnormal uncontrolled proliferation of any type of cells in the human body [3]. It is caused by external factors, such as smoking, infectious organisms, pollution, and radiation; it is also caused by internal factors, such as immune conditions, hormones, and genetic mutation [3].
    [Show full text]
  • Repositioning Fda-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome
    Author Manuscript Published OnlineFirst on December 15, 2016; DOI: 10.1158/1535-7163.MCT-16-0588 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. REPOSITIONING FDA-APPROVED DRUGS IN COMBINATION WITH EPIGENETIC DRUGS TO REPROGRAM COLON CANCER EPIGENOME Noël J.-M. Raynal1,2, Elodie M. Da Costa2, Justin T. Lee1, Vazganush Gharibyan3, Saira Ahmed3, Hanghang Zhang1,Takahiro Sato1, Gabriel G. Malouf4, and Jean-Pierre J. Issa1 1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA, 19140, USA. 2Département de pharmacologie, Université de Montréal and Sainte-Justine University Hospital Research Center, 3175, Chemin de la Côte-Sainte- Catherine, Montréal (Québec) H3T 1C5, Canada. 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. 4Department of Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, University Pierre and Marie Curie (Paris VI), Institut Universitaire de cancérologie, AP-HP, Paris, France. Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). Corresponding Author: Noël J.-M. Raynal, Département de Pharmacologie, Université de Montréal , Centre de recherche de l’Hôpital Sainte-Justine, 3175, Chemin de la Côte-Sainte-Catherine, Montréal (Québec), H3T 1C5, Canada. Phone : (514) 345-4931 ext. 6763. Email : [email protected] Running title: High-throughput screening for epigenetic drug combinations Key words: Drug repurposing, Drug combination, High-throughput drug screening, Epigenetic therapy The authors declare no potential conflicts of interest. 1 Downloaded from mct.aacrjournals.org on September 23, 2021.
    [Show full text]
  • Recent Advances in Arsenic Trioxide Encapsulated Nanoparticles As Drug Delivery Agents to Solid Cancers
    Available online at www.jbr-pub.org Open Access at PubMed Central The Journal of Biomedical Research, 2017 31(3): 177–188 Review Article Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers Anam Akhtar, Scarlet Xiaoyan Wang, Lucy Ghali, Celia Bell, Xuesong Wen✉ Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK. Abstract Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation. However, the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers. This is due to arsenic's rapid clearance by the body's immune system before reaching the tumor site. Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success. This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells. Different approaches that have been employed to increase arsenic's efficacy, specificity and bioavailability to solid cancer cells were evaluated and compared. The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed. Keywords: arsenic trioxide, solid cancer, nanotechnology, drug delivery, liposome Introduction Despite being the mainstay of materia medica since the past 2,400 years, ATO faced an escalating decline in Arsenic is a naturally occurring metalloid found as a its use as a therapeutic agent in the twentieth century [1] trace element in the earth's crust .
    [Show full text]
  • Fotemustine, Teniposide and Dexamethasone Versus High-Dose Methotrexate Plus Cytarabine in Newly Diagnosed Primary CNS Lymphoma: a Randomised Phase 2 Trial
    Journal of Neuro-Oncology https://doi.org/10.1007/s11060-018-2970-x CLINICAL STUDY Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial Jingjing Wu1 · Lingling Duan1 · Lei Zhang1 · Zhenchang Sun1 · Xiaorui Fu1 · Xin Li1 · Ling Li1 · Xinhua Wang1 · Xudong Zhang1 · Zhaoming Li1 · Hui Yu1 · Yu Chang1 · Feifei Nan1 · Jiaqin Yan1 · Li Tian1 · Xiaoli Wang1 · Mingzhi Zhang1 Received: 25 March 2018 / Accepted: 5 August 2018 © The Author(s) 2018 Abstract Objective This prospective, randomized, controlled and open-label clinical trial sought to evaluate the tolerability and efficacy of the FTD regimen (fotemustine, teniposide and dexamethasone) compared to HD-MA therapy (high-dose metho- trexate plus cytarabine) and to elucidate some biomarkers that influence outcomes in patients with newly diagnosed primary CNS lymphoma. Methods Participants were stratified by IELSG risk score (low versus intermediate versus high) and randomly assigned (1:1) to receive four cycles of FTD or HD-MA regimen. Both regimens were administered every 3 weeks and were followed by whole-brain radiotherapy. The primary endpoints were overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results Between June 2012, and June 2015, 52 patients were enrolled, of whom 49 patients were randomly assigned and analyzed. Of the 49 eligible patients, no significant difference was observed in terms of ORR between FTD (n = 24) and HD-MA (n = 25) groups (88% versus 84%, respectively, P = 0.628). Neither the 2-year PFS nor the 3-year OS rate differed significantly between FTD and HD-MA groups (37% versus 39% for 2-year PFS, P = 0.984; 51% versus 46% for 3-year OS, P = 0.509; respectively).
    [Show full text]
  • The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin As a Biomimetic Carrier for the Drug
    biomolecules Article The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin as a Biomimetic Carrier for the Drug Marta Rubio-Camacho, José A. Encinar , María José Martínez-Tomé, Rocío Esquembre * and C. Reyes Mateo * Instituto e investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández (UMH), E-03202 Elche, Spain; [email protected] (M.R.-C.); [email protected] (J.A.E.); [email protected] (M.J.M.-T.) * Correspondence: [email protected] (R.E.); [email protected] (C.R.M.); Tel.: +34-966-652-475 (R.E.); +34-966-658-469 (C.R.M.) Received: 18 June 2020; Accepted: 8 July 2020; Published: 9 July 2020 Abstract: The interaction of temozolomide (TMZ) (the main chemotherapeutic agent for brain tumors) with blood components has not been studied at the molecular level to date, even though such information is essential in the design of dosage forms for optimal therapy. This work explores the binding of TMZ to human serum albumin (HSA) and alpha-1-acid glycoprotein (AGP), as well as to blood cell-mimicking membrane systems. Absorption and fluorescence experiments with model membranes indicate that TMZ does not penetrate into the lipid bilayer, but binds to the membrane surface with very low affinity. Fluorescence experiments performed with the plasma proteins suggest that in human plasma, most of the bound TMZ is attached to HSA rather than to AGP. This interaction is moderate and likely mediated by hydrogen-bonding and hydrophobic forces, which increase the hydrolytic stability of the drug.
    [Show full text]
  • Prodrugs: a Challenge for the Drug Development
    PharmacologicalReports Copyright©2013 2013,65,1–14 byInstituteofPharmacology ISSN1734-1140 PolishAcademyofSciences Drugsneedtobedesignedwithdeliveryinmind TakeruHiguchi [70] Review Prodrugs:A challengeforthedrugdevelopment JolantaB.Zawilska1,2,JakubWojcieszak2,AgnieszkaB.Olejniczak1 1 InstituteofMedicalBiology,PolishAcademyofSciences,Lodowa106,PL93-232£ódŸ,Poland 2 DepartmentofPharmacodynamics,MedicalUniversityofLodz,Muszyñskiego1,PL90-151£ódŸ,Poland Correspondence: JolantaB.Zawilska,e-mail:[email protected] Abstract: It is estimated that about 10% of the drugs approved worldwide can be classified as prodrugs. Prodrugs, which have no or poor bio- logical activity, are chemically modified versions of a pharmacologically active agent, which must undergo transformation in vivo to release the active drug. They are designed in order to improve the physicochemical, biopharmaceutical and/or pharmacokinetic properties of pharmacologically potent compounds. This article describes the basic functional groups that are amenable to prodrug design, and highlights the major applications of the prodrug strategy, including the ability to improve oral absorption and aqueous solubility, increase lipophilicity, enhance active transport, as well as achieve site-selective delivery. Special emphasis is given to the role of the prodrug concept in the design of new anticancer therapies, including antibody-directed enzyme prodrug therapy (ADEPT) andgene-directedenzymeprodrugtherapy(GDEPT). Keywords: prodrugs,drugs’ metabolism,blood-brainbarrier,ADEPT,GDEPT
    [Show full text]
  • Natural Products. a History of Success and Continuing Promise for Drug Discovery and Development
    Natural Products. A History of Success and Continuing Promise for Drug Discovery and Development Gordon M. Cragg NIH Special Volunteer [email protected] David J. Newman Natural Products Branch Developmental Therapeutics Program National Cancer Institute EARLY DOCUMENTATION OF USE OF MEDICINAL PLANTS http://www.nlm.nih.gov/hmd/collections/archives/index.html • Mesopotamian ~2,600 B. C. E. • Egyptian ~ 1,800 B. C. E. • Chinese – ~1,100 B. C. E. and continuing • Indian ~ 1,000 B. C. E. and continuing • Greek ~ 500 B. C. E. Greco-Roman expertise preserved and coordinated with other traditions by Islamic cultures during the Dark Ages ~ 400-1,100 CE Avicenna. Persian pharmacist, physician, poet, philosopher author: canon medicinae – “final codification of Greco-Roman medicine” Great Moments in Pharmacy Collection APhA Traditional Medicine and Drug Discovery • 80% of the world population resides in developing countries • 80% of people in developing countries utilize plants to meet their primary health care needs • Global pop. ca. 7 billion ca. 4.5 billion people utilize plants to meet their primary health care needs Farnsworth NR, et al. Medicinal Plants in Therapy. Bull. W.H.O. 63:965-981 (1985) Fabricant and Farnsworth, EnViron. Health Perspect. 109, 69-75 (2001) Cordell and Clovard, J. Nat. Prod., 75, 514-525 (2012) Norman Farnsworth 1800s. Discovery of some active principles of major herbal preparations Newman and Cragg. Natural Product Chemistry for Drug Discovery, eds. Buss and Butler, M. S., Royal Soc. Chem., Cambridge, 2010, pp. 3-27 European chemists (apothecaries) revolutionized drug discovery and development. 1817. Sertϋrner reports isolation of morphine from Papaver somniferum.
    [Show full text]
  • Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
    Volume 2 (2012) // Issue 1 // e-ISSN 2224-3453 Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro- oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of NeuroOncology Magazine 2012; 2 (1) 25-36 Homepage: www.kup.at/ journals/eano/index.html OnlineOnline DatabaseDatabase FeaturingFeaturing Author,Author, KeyKey WordWord andand Full-TextFull-Text SearchSearch THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY Member of the Chemotherapy and Polyneuropathies Chemotherapy and Polyneuropathies Wolfgang Grisold1, Stefan Oberndorfer2, Anthony J Windebank3 Abstract: Peripheral neuropathies induced by taxanes) immediate effects can appear, caused to be caused by chemotherapy or other mecha- chemotherapy (CIPN) are an increasingly frequent by different mechanisms. The substances that nisms, whether treatment needs to be modified problem. Contrary to haematologic side effects, most frequently cause CIPN are vinca alkaloids, or stopped due to CIPN, and what symptomatic which can be treated with haematopoetic taxanes, platin derivates, bortezomib, and tha- treatment should be recommended. growth factors, neither prophylaxis nor specific lidomide. Little is known about synergistic neu- Possible new approaches for the management treatment is available, and only symptomatic rotoxicity caused by previously given chemo- of CIPN could be genetic susceptibility, as there treatment can be offered. therapies, or concomitant chemotherapies. The are some promising advances with vinca alka- CIPN are predominantly sensory, duration-of- role of pre-existent neuropathies on the develop- loids and taxanes. Eur Assoc Neurooncol Mag treatment-dependent neuropathies, which de- ment of a CIPN is generally assumed, but not 2012; 2 (1): 25–36. velop after a typical cumulative dose. Rarely mo- clear.
    [Show full text]